바이오니아

064550KOSDAQ

40.0 / 100

Reference Date: 2026-10-23

Financial Score15.5 / 40

News Sentiment12.5 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 20.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

BioNia is a biopharmaceutical company specializing in developing solutions for disease diagnosis, treatment, and prevention based on core biotechnology, with key businesses in life science research products, molecular diagnostics, probiotics, and RNAi-based drug development. Over 33 years, it has accumulated advanced genetic technologies, supplying PCR equipment, molecular diagnostic kits, and expanding into new areas like synthetic biology bioprinting and RNA-based cosmetics.

Number of Employees

362people

Average Salary

52.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

110.83Industry Average 15.000.0Point

7.4x industry avg (risky)

PBR

0.83Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

0.75Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

33.85Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲12.0% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼790.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -3.5% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (15%, downtrend)

Current 7,330Won52-week high 15,50052-week low 5,790

1-month return0.0Point

1m -20.24% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-12
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-12